Tilt Investment Management Holdings PBC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tilt Investment Management Holdings PBC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 437 shares of the biopharmaceutical company’s stock after selling 129 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Regeneron Pharmaceuticals were worth $384,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in REGN. Ronald Blue Trust Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares during the period. Drive Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares during the last quarter. Cassia Capital Partners LLC lifted its stake in Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 13 shares during the period. Sutton Wealth Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares during the period. Finally, Clearview Wealth Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $3.63 during mid-day trading on Thursday, reaching $897.56. The company’s stock had a trading volume of 248,925 shares, compared to its average volume of 492,167. The stock has a 50-day moving average of $955.19 and a two-hundred day moving average of $890.52. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a market capitalization of $98.52 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $10.96 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Bank of America upped their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Barclays raised their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $976.41.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Joseph L. Goldstein sold 2,707 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares in the company, valued at approximately $6,062,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares in the company, valued at $6,062,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock worth $13,124,641 in the last three months. 8.83% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.